Study Title
Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer NCT02161679
Trial Description
This is a Phase II, open-label study that evaluates the safety and efficacy of IMMU-132 alone and in combination with carboplatin in patients with triple-negative breast cancer. IMMU132 will be administered once-weekly for the first 2 weeks of 3-week treatment cycles.
For those patients assigned to also receive carboplatin, will receive it on the same schedules starting 30 minutes after the completion of IMMU-132 administration. Patients may receive up to a maximum total of 8 cycles.
This trial is sponsored by Immunomedics, Inc.®.
Study Data
- Condition: Triple Negative Breast Cancer
- Interventions:
- Drugs used in this trial
- Sacituzumab govitecan (IMMU-132, Immunomedics, Inc.®)
- Carboplatin
- Drugs used in this trial
- Phase: II
- Enrollment: 80
- Start: August 2016
- Estimated Completion: August 2018
- Last verified: October 2015
- Last Updated: October 2015
Study Schematic
Click here to Return to Drug map
Last Editorial review: November 9, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
